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METHODOLOGY Open Access
A novel tetracycline-responsive transgenic
mouse strain for skeletal muscle-specific
gene expression
Masahiro Iwata1,3,4†, Davis A. Englund1,2†, Yuan Wen1,3, Cory M. Dungan1,2, Kevin A. Murach1,2, Ivan J. Vechetti Jr1,3,
Christopher B. Mobley1,3, Charlotte A. Peterson1,2 and John J. McCarthy1,3*
Abstract
Background: The tetracycline-responsive system (Tet-ON/OFF) has proven to be a valuable tool for manipulating
gene expression in an inducible, temporal, and tissue-specific manner. The purpose of this study was to create and
characterize a new transgenic mouse strain utilizing the human skeletal muscle α-actin (HSA) promoter to drive
skeletal muscle-specific expression of the reverse tetracycline transactivator (rtTA) gene which we have designated
as the HSA-rtTA mouse.
Methods: To confirm the HSA-rtTA mouse was capable of driving skeletal muscle-specific expression, we crossed
the HSA-rtTA mouse with the tetracycline-responsive histone H2B-green fluorescent protein (H2B-GFP) transgenic
mouse in order to label myonuclei.
Results: Reverse transcription-PCR confirmed skeletal muscle-specific expression of rtTA mRNA, while single-fiber
analysis showed highly effective GFP labeling of myonuclei in both fast- and slow-twitch skeletal muscles. Pax7
immunohistochemistry of skeletal muscle cross-sections revealed no appreciable GFP expression in satellite cells.
Conclusions: The HSA-rtTA transgenic mouse allows for robust, specific, and inducible gene expression across
muscles of different fiber types. The HSA-rtTA mouse provides a powerful tool to manipulate gene expression in
skeletal muscle.
Keywords: Skeletal muscle-specific, Tetracycline-responsive
Background
Since the original description, the tetracycline-responsive
system (Tet-ON/OFF) has proven to be a powerful tool in
biomedical research because of the ability to manipulate
gene expression within the mouse in both a temporal and
tissue-specific manner [1, 2]. Although a number of
skeletal muscle-specific Tet-ON/OFF mice have been
described, they have used promoters that drive primarily
fast-twitch, type II gene expression; in addition, these mice
are not readily available [3, 4]. To address these limitations,
we generated a transgenic mouse which uses the human
skeletal muscle α-actin (HSA) promoter to drive skeletal
muscle-specific expression of the reverse-tetracycline
transactivator (rtTA) which we have designated as the
HSA-rtTA mouse. To validate the HSA-rtTA mouse, we
crossed it with the tetracycline-responsive histone H2B-
green fluorescent protein (TRE-H2B-GFP) mouse to easily
visualize and quantify myonuclear GFP expression follow-
ing doxycycline treatment [5]. As expected, rtTA mRNA
was highly expressed in skeletal muscle as > 95% of myo-
nuclei were GFP-positive in both type I and type II mus-
cles. Importantly, an extremely small number of satellite
cells appeared to be GFP-positive in soleus muscle
cross-section, thus confirming the ability of the HSA-rtTA
mouse to drive robust skeletal muscle-specific expression
of a tetracycline-responsive gene of interest.
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Methods
Generating the HSA-rtTA transgenic mouse
As previously described by us for the HSA-MerCreMer
transgene, the promoter and first exon (− 2,000 to + 239
relative to the transcription start site) of the human skeletal
muscle α-actin (HSA) gene was amplified from human
genomic DNA (Promega, Madison, WI, USA) and cloned
into the ClaI site of the SG5 expression vector (Agilent
Technologies, Santa Clara, CA, USA) upstream of the
β-globin intron II [6]. The rtTA cDNA was amplified from
the pCMV-Tet3G expression vector (Takara Bio, Mountain
View, CA, USA) and cloned into the EcoRI/BamHI sites of
the pSG5-HSA plasmid to generate the pSG5-HSA-rtTA;
the rtTA insert was subsequently sequenced for verifica-
tion. The HSA-rtTA transgene (Fig. 1) was released from
the plasmid by HindIII/NsiI enzyme digestion, gel-purified
using the QIAquick Gel Extraction Kit according to the
manufacturer’s directions (Qiagen, Valencia, CA, USA),
and then provided to the University of Michigan Trans-
genic Animal Model Core for microinjection. F1 generation
pups were screened by PCR for the presence of the rtTA
sequence using genomic DNA isolated from tail snips with
the following primers: F, 5′ATGTCTAGACTGGACAAG
AGCA AAG-3′; R, 5′-TTACCCGGGGAGCATGTC-3′
generating a product of 747 bp. Eight F1 pups were positive
for the HSA-rtTA transgene and subsequently crossed to
the TRE-H2B-GFP mouse (The Jackson Laboratory,
stock number 005104) to determine the ability to
drive H2B-GFP expression following doxycycline
treatment. Of the eight founder lines, line 6 was iden-
tified as driving robust H2B-GFP expression in both
slow- and fast-twitch muscles of the lower hind limbs
and was further characterized as described below. For
convenience, the HSA-rtTA/TRE-H2B-GFP mouse is
referred to as the HSA-GFP mouse.
Doxycycline treatment
To induce H2B-GFP expression, 3–10-month-old HSA-
GFP mice were administered doxycycline (0.5 mg/mL) in
drinking water supplemented with 2% sucrose for 3 weeks.
Tissue was collected immediately upon completion of
doxycycline treatment. To determine the earliest time of
GFP induction, skeletal muscle was collected after 12 h or
24 h following doxycycline administration.
Analysis of rtTA gene expression
Total RNA was isolated from skeletal muscles (gastrocne-
mius, plantaris, soleus, extensor digitorum longus (EDL),
tibialis anterior (TA), diaphragm and heart, and non-
muscle tissue (brain, liver, lung, stomach, spleen, kidney,
and fat) of HSA-GFP mice. Tissue was immediately frozen
in liquid nitrogen upon excision and subsequently homog-
enized using a Bullet Blender (Next Advance Inc., Averill
Park, NY, USA) in Direct-zol (Zymo Research, Irvine, CA,
USA) according to the manufacturer’s instructions. Total
RNA concentration and quality were determined by nano-
Vue spectrophotometer (GE Healthcare, USA). cDNA was
synthesized from 1 μg of total RNA using the SuperScript®
VILO IV™ (ThermoFisher Scientific, Waltham, MA, USA)
according to the manufacturer’s instructions. PCR analysis
of rtTA mRNA accumulation used the following primers:
F, 5′- GAGGAACAGGAGC ATCAAGTAG-3′; R, 5′- GT
CAGCAGGCAGCATATCA-3′ and generated a 270 bp
product.
Single fiber analysis
GFP+ and GFP− myonuclei were counted on isolated
single muscle fibers as previously described by us [7].
Briefly, hind limb muscles were fixed in situ at resting
length in 4% paraformaldehyde for 48 h. Fixed whole
muscles were removed from the hind limb, dissected,
and dissociated in 40% sodium hydroxide with manual
manipulation at room temperature. Isolated fibers were
then stained with DAPI and carefully pipetted on to
glass slides and covered using Vectashield (Vector
Laboratories, Burlingame, CA, USA).
Immunohistochemistry
For immunohistochemistry (IHC) analyses, the various
hind limb muscles were covered in Tissue-Tek optimal
cutting temperature compound (Sakura Finetek, Tor-
rance, CA, USA) and pinned at resting length to a cork
covered in aluminum foil. Muscles were frozen in liquid
nitrogen-cooled isopentane and stored at − 80 °C. Mus-
cles were sectioned at the mid-belly on a cryostat at −
23 °C. Frozen muscle sections (7 μm) were air-dried for
at least 1 h and stored at − 20 °C. For Pax7/DAPI IHC,
muscles were first fixed in 4% paraformaldehyde for
7 min and then subjected to epitope retrieval. Following
HSA promoter BGI ACre MerrtTA
Fig. 1 A schematic of the HSA-rtTA transgene. The promoter and first exon (− 2,000 to + 239 relative to the transcription start site) of the human
skeletal muscle α-actin (HSA) gene regulates expression of an optimized reverse tetracycline transactivator (rtTA) gene which has been reported
to be sevenfold more active and 100-fold more doxycycline sensitive than the original Tet-On system [8]. The β-globin intron ΙΙ (BGI) and poly(A)
tail were incorporated into the transgene to ensure proper splicing and transcript stability, respectively. The positions of the PCR primers used for
genotyping are indicated by half-arrows
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epitope retrieval in sodium citrate (10 mM, pH 6.5) for
20 min at 92 °C, endogenous peroxidases were blocked for
7 min with 3% hydrogen peroxide in phosphate-buffered
saline (PBS), followed by 1 h with 1% Tyramide Signal
Amplification (TSA) blocking reagent (TSA kit, T20935,
Invitrogen) supplemented with Mouse-on-Mouse (MoM)
IgG blocking reagent (Vector Laboratories, Burlingame,
CA, USA). Sections were washed in PBS and incubated
overnight with mouse anti-Pax7 IgG1 antibody (1:100,
Developmental Studies Hybridoma Bank (DSHB), Iowa
City, IA, USA) and chicken anti-GFP antibody (1:200,
Abcam, Cambridge, MA, USA) diluted in 1% TSA block-
ing reagent. It was necessary to use anti-GFP antibody to
detect GFP expression because the antigen retrieval
process quenched the GFP signal. The following day,
sections were washed with PBS, incubated for 70 min in
goat anti-mouse IgG1 biotinylated secondary antibody
(1:1000, 115-065-205, Jackson ImmunoResearch, West
Grove, PA, USA) and anti-chicken GFP secondary anti-
body, (1:250, Abcam), washed in PBS, incubated for 1 h in
streptavidin-horseradish peroxidase (1:500, S-911, Invitro-
gen) diluted in PBS, washed again in PBS, then incubated
for 15 min in TSA Alexa Fluor 594 (1:500, TSA kit, Invi-
trogen) in the supplied amplification diluents. Sections
were stained with DAPI (1:10,000 in PBS, D35471, Invitro-
gen) for 5 min and mounted with VectaShield fluorescent
mounting media.
Image acquisition and quantification
GFP+/DAPI+ and GFP−/DAPI+ myonuclei from ~ 10 iso-
lated fibers from four doxycycline-treated mice (two male
and two female) were counted for each muscle, resulting
in a range of 202–452 myonuclei being analyzed across
muscles. Twelve to 15 single fibers from two untreated
mice (1 male and 1 female) were analyzed for each muscle,
resulting in a range of 254–600 myonuclei being analyzed
across muscles. For the time course analysis, 35
diaphragm fibers (n = 2) were counted representing a total
of 906 myonuclei, whereas 37 plantaris fibers (n = 2) were
counted representing a total of 1294 myonuclei. For IHC,
images were captured at × 20 magnification using a Zeiss
upright fluorescent microscope (Zeiss Axio Imager M1,
Oberkochen, Germany). Whole muscle sections were ob-
tained using the mosaic function in Zeiss Zen 2.3 imaging
software. Satellite cells (Pax7+/DAPI+) and GFP+ satellite
cells were identified manually using Zen software tools.
Results
Skeletal muscle-specific rtTA transgene
To generate the skeletal muscle-specific rtTA transgene
for microinjection, we cloned downstream of the human
skeletal muscle α-actin (HSA) promoter a third gener-
ation rtTA gene that was reported to be sevenfold more
active and 100-fold more doxycycline sensitive than the
original rtTA [8]. A schematic of the HSA-rtTA trans-
gene is shown in Fig. 1.
Skeletal muscle-specific expression of rtTA mRNA
We determined by reverse transcription-PCR the expres-
sion of rtTA mRNA in several hind limb muscles, the
diaphragm, fat, and several other non-muscle organs. As
shown in Fig. 2, rtTA mRNA was highly expressed in all
of the hind limb muscles examined and to a lesser extent
in the diaphragm and heart. As expected, rtTA expression
was not detectable in any non-muscle tissues.
Effective labeling of myonuclei in hind limb skeletal
muscles
Having established that rtTA was highly enriched in skel-
etal muscle, we sought to determine how effective the
HSA-rtTA transgene was in driving H2B-GFP expression
in response to doxycycline treatment. Given that
H2B-GFP is nuclearly localized, we used the percentage of
myonuclei that were GFP+ on single fibers as a measure
Fig. 2 Skeletal muscle-specific expression of rtTA. PCR analysis of rtTA mRNA expression of different tissues from the HSA-GFP transgenic mouse
showed high levels of expression in skeletal muscle (gastrocnemius, soleus, plantaris, tibialis anterior (TA), and extensor digitorum longus (EDL)),
modest expression in the diaphragm, very low expression in the heart, and not detectable in non-muscle tissue (brain, fat, lung, liver, stomach,
spleen, and kidney)
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of the effectiveness of the HSA-rtTA transgene to induce
expression of a tetracycline-responsive gene. Following
fixation, single fibers were isolated from the plantaris,
gastrocnemius, soleus, tibialis anterior (TA), and extensor
digitorum longus (EDL) of doxycycline-treated mice and
then stained with DAPI to identify myonuclei. As shown
in Fig. 3a, b, greater than 95% (range of 96.4–97.9%) of
myonuclei were GFP+ across all muscles from
A
B
Fig. 3 HSA-rtTA transgene drives robust myofiber expression of tetracycline-responsive H2B-GFP transgene. a Representative single fiber images
of hind limb muscles taken from HSA-GFP mice (n = 4) treated with doxycycline. Single fiber images show robust myonuclear GFP expression in
muscles composed of slow- and fast-twitch fibers. b Quantification of GFP+ myonuclei of single fibers from hind limb skeletal muscles (plantaris,
gastrocnemius, soleus, tibialis anterior (TA), and extensor digitorum longus (EDL)) of HSA-GFP mice showed greater than 95% of all DAPI+
myonuclei within a fiber were GFP+. The gray bar represents the average percentage of GFP-positive myonuclei (n = 4) for each muscle
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doxycycline-treated HSA-GFP mice. We observed no GFP
+ myonuclei in skeletal muscle single fibers of untreated
HSA-GFP mice demonstrating tight regulation of
tetracycline-responsive H2B-GFP gene (data not shown).
These findings confirm the HSA-rtTA mouse is capable of
driving robust expression of a tetracycline-responsive gene
in adult skeletal muscles composed of both slow- and
fast-twitch fibers.
GFP labeling is highly specific to myonuclei
To determine if the HSA-rtTA drove expression of the
H2B-GFP transgene in satellite cells, we performed immu-
nohistochemistry on both soleus and plantaris muscle
cross-sections for DAPI, Pax7, and GFP. As shown in Fig. 4,
GFP labeling did not localize with Pax7 staining; however,
in the soleus, of the 190 satellite cells counted, three Pax7+






Fig. 4 GFP expression is specific to myonuclei in HSA-GFP mice. Representative muscle cross-section images of the plantaris and soleus muscles
from HSA-GFP mice treated with doxycycline (n = 3). As indicated by white arrows, DAPI+/GFP+ myonuclei (green) did not show co-localization
with DAPI+/Pax7+ satellite cells (pink). These results confirm that the HSA-rtTA transgene is able to drive myofiber-specific expression of a
tetracycline-response gene
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HSA-rtTA drives highly myofiber-specific expression of a
tetracycline-responsive transgene.
Rapid GFP labeling of myonuclei
To determine the time course of GFP labeling of myo-
nuclei, skeletal muscle was collected from HAS-GFP
mice after 12 or 24 h of doxycycline treatment. As
shown in Fig. 5a, b, approximately 90% of myonuclei in
the plantaris muscle were GFP-positive after 24 h of
doxycycline treatment; in contrast, GFP expression was
not detected following 12 h of doxycycline administra-
tion (data not shown). We also examined whether GFP
expression followed the same time course of induction
given the modest expression of rtTA mRNA in the
diaphragm (see Fig. 2). While GFP expression was not as
robust as that observed in the plantaris, 60% of myonu-
clei of the diaphragm were GFP-positive following 24 h
of doxycycline treatment, consistent with the lower rtTA
mRNA expression (see Fig. 5a–b).
Discussion
The purpose of this study was to characterize a new
skeletal muscle-specific Tet-ON mouse. The human
skeletal muscle α-actin (HSA) promoter was used to
drive skeletal muscle-specific expression of the reverse-
tetracycline transactivator (rtTA), designated as the
HSA-rtTA mouse. The HSA promoter contains 2,000 bp
of human skeletal α-actin 5′-flanking sequence plus the
first exon and 149 bp of the first intron and was first re-
ported by Muscat and Kedes to promote robust, skeletal
muscle-specific expression [9]. We choose to use the
HSA promoter because we previously showed it was able
to drive effective Cre-mediated recombination in both
slow- and fast-twitch fibers with minimal expression in
the heart [6]. This is an important improvement over a
previous skeletal muscle-specific Tet-ON mouse (MCK-
rtTA) which only allowed over-expression of a gene of
interest in fast-twitch, type IIb fibers [10]. Together with
the HSA-CreER mouse, the HSA-rtTA mouse now pro-
vides the ability to perform loss- and gain-of-function
studies, respectively, to determine the in vivo function of
a gene of interest in skeletal muscle fibers [6, 11]. The
complement to these two inducible, skeletal muscle-spe-
cific mice are the satellite cell-specific inducible Cre and
Tet-ON mice; however, while the satellite cell-specific
Cre mouse has been extensively used, to the best of our
A
B
Fig. 5 Rapid GFP labeling of myonuclei. a Representative single fiber images of plantaris and diaphragm muscles taken from HSA-GFP mice (n =
2) treated with doxycycline for 24 h. b Quantification of GFP+ myonuclei showed ~ 90% of myonuclei were GFP-positive in myofibers from the
plantaris with 60% of myonuclei GFP-positive in myofibers isolated from the diaphragm
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knowledge, the satellite cell-specific Tet-ON mouse has
yet to be fully characterized [12–15]. Collectively, these
inducible, skeletal muscle-, and satellite cell-specific
mice provide powerful tools to manipulate in vivo gene
expression to identify and better understand the mecha-
nisms regulating skeletal muscle biology in health and
disease.
While 3 weeks of doxycycline treatment was able to in-
duce > 95% GFP labeling of myonuclei, we wanted to know
the earliest time point when GFP expression could be
detected following doxycycline administration. As shown in
Fig. 5, single fiber analysis revealed myonuclear GFP
expression was observed as early as 24 h post-doxycycline
exposure; in contrast, we observed no GFP expression at
12 h post-doxycycline treatment (data not shown). These
results demonstrate the HSA-rtTA mouse is very respon-
sive to doxycycline and will provide the ability to study the
relative early (~ 24 h) effects of gene activation on a given
biological process. For example, the HSA-rtTA mouse
could be used to study how the early (~ 24 h) activation of
Akt1 (using the tetracycline-responsive, constitutively active
Akt1 mouse, TRE-myrAkt1) affects the hypertrophic
response in skeletal muscle as Akt1 is typically not activated
until 48 h [16, 17].
In contrast to the strong rtTA expression in hind limb
muscles, there was modest, but detectable, expression of
rtTA mRNA in the diaphragm. We do not know the rea-
son why rtTA expression is lower in the diaphragm
compared to hind limb muscles, but it may reflect a
limitation of the HSA promoter to drive high levels of
expression in the diaphragm. We also found compara-
tively lower expression of Cre in the diaphragm of the
HSA-CreER mouse, consistent with the idea that the
HSA promoter is not as robust in the diaphragm as it is
in other muscles. Despite low rtTA expression, we still
observed ~ 60% GFP labeling of diaphragm myonuclei
after only 24 h of doxycycline treatment. This result in-
dicates the HSA-rtTA mouse is a useful tool for investi-
gators studying the diaphragm.
The HSA-rtTA transgenic mouse allows for inducible,
myofiber-specific gene expression in both slow- and
fast-twitch muscles. The HSA-rtTA mouse will provide
researchers with a powerful tool to reversibly induce
gene expression in an effort to better understand skeletal
muscle biology. The HSA-rtTA mouse will be freely
available upon request.
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